These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25658540)

  • 1. IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals.
    Machmach K; Abad-Molina C; Romero-Sánchez MC; Dominguez-Molina B; Moyano M; Rodriguez MM; Rafii-El-Idrissi Benhnia M; Jimenez-Mejias ME; Vidal F; Muñoz-Fernández MA; Genebat M; Viciana P; González-Escribano MF; Leal M; Ruiz-Mateos E
    Clin Microbiol Infect; 2015 Mar; 21(3):289.e1-4. PubMed ID: 25658540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians.
    Knapp S; Zakaria Z; Hashem M; Zaghla H; Khakoo SI; Waked I; Thursz M; Abdelwahab SF
    Hepatol Int; 2015 Apr; 9(2):251-7. PubMed ID: 25788203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C.
    Krämer B; Nischalke HD; Boesecke C; Ingiliz P; Voigt E; Mauss S; Stellbrink HJ; Baumgarten A; Rockstroh JK; Spengler U; Nattermann J
    AIDS; 2013 Nov; 27(17):2817-9. PubMed ID: 23939236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
    Franco S; Aparicio E; Parera M; Clotet B; Tural C; Martinez MA
    AIDS; 2014 Jan; 28(1):133-6. PubMed ID: 24072198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients.
    Bordi L; Caglioti C; Garbuglia AR; Lapa D; Castilletti C; Taibi C; Capobianchi MR; Lalle E
    PLoS One; 2015; 10(2):e0117397. PubMed ID: 25675103
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Meissner EG; Chung D; Tsao B; Haas DW; Utay NS
    AIDS Res Hum Retroviruses; 2021 Mar; 37(3):184-188. PubMed ID: 33066718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Interleukin-28B polymorphism on Interleukin-28 expression and immunological recovery amongst HIV-1-infected individuals following antiretroviral therapy.
    Srinidhi BV; Fletcher GJ; Sachidanantham J; Rupali P; Ramalingam VV; Demosthenes JP; Abraham OC; Pulimood SA; Rebekah G; Kannangai R
    Indian J Med Microbiol; 2017; 35(4):580-584. PubMed ID: 29405153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients.
    Nozawa Y; Umemura T; Katsuyama Y; Shibata S; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Yoshizawa K; Ota M; Tanaka E
    Tissue Antigens; 2014 Jan; 83(1):45-8. PubMed ID: 24355007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection.
    Real LM; Herrero R; Rivero-Juárez A; Camacho Á; Macías J; Vic S; Soriano V; Viedma S; Guardiola JM; Fibla J; Rivero A; Pineda JA; Caruz A
    AIDS; 2015 Sep; 29(14):1895-7. PubMed ID: 26372394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: negative influence of hepatitis C infection.
    Farías AA; Kremer LE; Allende L; Díaz Mdel P; Pisano MB; Contigiani MS; Ré VE
    Trans R Soc Trop Med Hyg; 2013 Jul; 107(7):432-7. PubMed ID: 23761392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers.
    Dominguez-Molina B; Tarancon-Diez L; Hua S; Abad-Molina C; Rodriguez-Gallego E; Machmach K; Vidal F; Tural C; Moreno S; Goñi JM; Ramírez de Arellano E; Del Val M; Gonzalez-Escribano MF; Del Romero J; Rodriguez C; Capa L; Viciana P; Alcamí J; Yu XG; Walker BD; Leal M; Lichterfeld M; Ruiz-Mateos E;
    Clin Infect Dis; 2017 Mar; 64(5):621-628. PubMed ID: 27986689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.
    Prokunina-Olsson L; Muchmore B; Tang W; Pfeiffer RM; Park H; Dickensheets H; Hergott D; Porter-Gill P; Mumy A; Kohaar I; Chen S; Brand N; Tarway M; Liu L; Sheikh F; Astemborski J; Bonkovsky HL; Edlin BR; Howell CD; Morgan TR; Thomas DL; Rehermann B; Donnelly RP; O'Brien TR
    Nat Genet; 2013 Feb; 45(2):164-71. PubMed ID: 23291588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
    Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
    Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No Association of IFNL4 Genotype With Opportunistic Infections and Cancers Among Men With Human Immunodeficiency Virus 1 Infection.
    Fang MZ; Jackson SS; Pfeiffer RM; Kim EY; Chen S; Hussain SK; Jacobson LP; Martinson J; Prokunina-Olsson L; Thio CL; Duggal P; Wolinsky S; O'Brien TR
    Clin Infect Dis; 2023 Feb; 76(3):521-527. PubMed ID: 36573283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy.
    Lee S; Saraswati H; Yunihastuti E; Gani R; Price P
    Clin Immunol; 2014 Dec; 155(2):149-59. PubMed ID: 25283333
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Rugwizangoga B; Andersson ME; Kabayiza JC; Nilsson MS; Ármannsdóttir B; Aurelius J; Nilsson S; Hellstrand K; Lindh M; Martner A
    Front Cell Infect Microbiol; 2019; 9():340. PubMed ID: 31637221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SNP RS12979860 related spontaneous clearance of hepatitis c virus infection in HCV/HIV-1 coinfected patients.
    Lapiński TW; Pogorzelska J; Kowalczuk O; Nikliński J; Flisiak R
    Przegl Epidemiol; 2013; 67(3):407-9, 517-9. PubMed ID: 24340551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy.
    Zhang S; van Sighem A; Kesselring A; Gras L; Prins JM; Hassink E; Kauffmann R; Richter C; de Wolf F; Reiss P;
    HIV Med; 2015 May; 16(5):265-72. PubMed ID: 25604160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.